Send to

Choose Destination

See 1 citation found by title matching your search:

Data Brief. 2017 Nov 14;16:369-375. doi: 10.1016/j.dib.2017.11.034. eCollection 2018 Feb.

Contemporary data on treatment practices for low-density lipoprotein cholesterol in 3867 patients who had suffered an acute coronary syndrome across the world.

Author information

Herzzentrum Ludwigshafen, Germany.
Institut für Herzinfarktforschung Ludwigshafen, Germany.
Merck & Co., Inc., Kenilworth, NJ, USA.
Rangueil Hospital, Toulouse University School of Medicine, Toulouse, France.
Department of Molecular Medicine University of Pavia, and Cardiac Intensive Care Unit and Laboratories for Experimental Cardiology, IRCCS Fondazione Policlinico San Matteo, Pavia, Italy.
Rutgers University, School of Public Health, Piscataway, NJ, USA.
MSD Ltd. Hoddesdon, UK.
Agile-1 for Merck & Co., Inc., Kenilworth, NJ, USA.
Sheikh Khalifa Medical City, Abu Dhabi, UAE.
Heart and Vascular Institute, Cleveland Clinic Abu Dhabi, UAE.
National Taiwan University Hospital, Taipei, Taiwan and Fu-Jen Catholic University Hospital, Taipei, Taiwan.
Yong Loo Lin School of Medicine, National University of Singapore, Singapore.
Department of Cardiology, National University Heart Center Singapore, National University Health System, Singapore.


DYSIS II ACS was a longitudinal, observational study in 3867 patients from 18 countries. They were being hospitalized after suffering an acute coronary syndrome. Evaluations were performed at the time of admission and again 120±15 days following the date of admission (the follow-up time point). 2521 patients were on active lipid lowering treatment (LLT) at admission. Mean atorvastatin dose was 22 mg per day and 2.7% received ezetimibe in combination with a statin. At discharge from hospital, 3767 patients received LLT expressed as a mean atorvastatin dose of 36 mg per day with 4.8% receiving ezetimibe on top of a statin. After 120 days, intensity in lipid lowering treatment was reduced to 32 mg per day with 4.9% of the patients receiving ezetimibe and a statin. Of note, during this 4-month follow up period, only 32% of all patients received laboratory lipid testing. 37% attained the low density lipoprotein cholesterol (LDL-C) target value of <70 mg/dl after 120 days. There are differences in the therapy administered as well as in the switch strategies when comparing the data from the respective countries studied.


Only one in three patients achieved the LDL-C target value following only marginal improvements in atorvastatin dose or combination therapy after an ACS event.


Global; Low-density lipoprotein cholesterol; Region; Statins; Treatment target

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center